← Oncology Approval Tracker

FDA DECISION ·

Xpovio

selinexor · Karyopharm Therapeutics

Accelerated approvalNew or expanded indicationDiffuse large B-cell lymphoma
Open LinkedIn brief ↓

1 min read · estimated

Sources

LATER FDA ACTION

Indication withdrawn on Apr 30, 2026

FDA Project Confirm ↗

APPROVED USE

What FDA approved

Adults with relapsed or refractory diffuse large B-cell lymphoma not otherwise specified, including disease arising from follicular lymphoma, after at least two systemic therapy lines.

LAMPGEN ANALYSIS

Why it matters

Added oral nuclear export inhibition for a heavily pretreated lymphoma population under accelerated approval.

What research teams should watch

Confirm histology and prior lines and schedule monitoring for cytopenias and electrolyte changes.

PRIMARY RECORDS

Sources